Spots Global Cancer Trial Database for A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Study ID: NCT06158516
Conditions
Study Description
Brief Summary: pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Changhai Hospital, Shanghai, , China
Contact Details
Name: Gang Jin, Doctor
Affiliation: Changhai Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jianming Xu, Doctor
Affiliation: Chinese PLA General Hosptial
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
